P2.07-016 Inmunotherapy: Which Is More Important, Choosing Patients Who Will Respond or Identifying Those Who Will Die Early?

Nivolumab has been approved in a second line, of non-small cell lung cancer (NSCLC) after the failure of the first line of platinum-based chemotherapy. The use of immunotherapy is assuming a new challenge in the clinical practice of the oncologist, who has to familiarize himself with a different toxicity profile than chemotherapy.The objective of this study is to describe the clinical characteristics of our patients, focusing on the toxicity profile found and trying to find something that will help us to identify patients who are going to have poor early evolution.